Breast Cancer PDX Models
A Champions Model Cohort
Advance your Breast Cancer drug development research using an extensive bank of meticulously curated Breast Cancer PDX models directly established from patient tumors.
Clinically Relevant Models
Living & diverse bank of clinically relevant models that correlate with clinical outcomes
Pretreated PDX Models
Established from tumor biopsies from patients pretreated with latest generation therapies
Multi-omic Characterization
Clinical annotations coupled with molecular datasets and in vivo responses
Advance your Beast Cancer Therapeutic Pipeline with Confidence
Champions Oncology has established a large cohort of patient breast cancer PDX models, with 121* models available to scientists for oncology research and drug development. These models are derived from patients with late-stage, primary, metastatic, and local metastatic tumors while retaining critical molecular features and alterations, making them therapeutically relevant. (*Model numbers fluctuate as our dataset continuously evolves.)
Champions' leading Breast Cancer PDX Models cohort showcases low-passage models, each reflecting key clinical characteristics, mutations, and pretreatment history.
-
Access to one of the largest bank of breast cancer models with clinically relevant molecular
and pathological characteristics on the market. -
Access to highly characterized PDX models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics, and Phosphoproteomics.
-
Includes models pretreated with advanced therapies like Tamoxifen, Carboplatin, Docetaxel, Trastuzumab, and more.